FinanceDrug Pricing Proposals Put Pharma at Greater Financial Risk
Efforts at the state and federal level to reduce prescription drug prices pose a financial risk for pharmaceutical companies, according...
FinanceHHS Proposal Could Kill PBM Rebates: Some Pleased, Others Concerned
The proposal would end safe-harbor protections for the rebates drug manufacturers pay to PBMs and add safe-harbor protections for drug...
FinanceQ4 Earnings Strong for Celgene Ahead of Bristol-Myers Squibb Deal
The Summit, New Jersey-based biotech giant released its Q4 2018 earnings report weeks after Bristol-Myers Squibb announced a $74 billion...
FinanceSecretive 'Rebate Trap' Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach
Drug companies routinely make hidden pacts with middlemen that effectively block patients from getting cheaper generic medicines.
Clinical CareHealthcare Marketing Expenditures Increase $12.2 Billion Over Past Two Decades
Pharmaceutical company marketing to healthcare professionals accounted for the largest portion of spending, set at $20.3 billion in 2016.
StrategyCivica Rx Adds 12 Health Systems as Founding Members
The alliance, which was formed last year by seven health systems and three philanthropic organizations, aims to tamp down drug...
Clinical CareWhen Medicine Makes Patients Sicker
The FDA is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a...
Azar Tries to Calm Concerns Over Proposal's Impact on HIV Drugs
Patient advocates warned the Medicare Part D proposal could undermine efforts to expand treatment for HIV and cancer.
FinanceWalmart, Express Scripts Sign Three-Year Prescription Drug Extension
The retail giant and St. Louis-based insurer announced plans Wednesday to continue their prescription drug contract through 2021.
StrategyPersonalized Medicine: A Potential Game Changer, Someday
There's a lot of talk about the potential for personalized medicine to lower drug costs.
Strategy3 Ways Your Hospital Can Contain Escalating Drug Prices and Shortages
What can hospital executives and clinicians do inside their hospital walls to tackle rising costs and inconsistent supplies?
Government Investigation Finds Flaws In the FDA's Orphan Drug Program
A third of all pharmaceutical spending in the U.S. will be on so-called rare-disease medicines in 2020, leading many to...